-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Anebulo Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2020 to Q3 2024.
- Anebulo Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.41M, a 5.17% increase year-over-year.
- Anebulo Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$8.18M, a 30.2% increase year-over-year.
- Anebulo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$8.31M, a 29.5% increase from 2023.
- Anebulo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$11.8M, a 72.5% decline from 2022.
- Anebulo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$6.83M, a 89% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)